Preference for pharmaceutical formulation and treatment process attributes

References

• Hixson-WallaceJADotsonJBBlakeySAEffect of regimen complexity on patient satisfaction and compliance with warfarin therapyClin Appl Thromb Hemost200171333711190902
   PubMed Web of Science ®Google Scholar
• MorrisLSSchulzRMMedication compliance: the patient’s perspectiveClin Ther19931535936068364951
   PubMed Web of Science ®Google Scholar
• RauePJSchulbergHCHeoMKlimstraSBruceMLPatients’ depression treatment preferences and initiation, adherence, and outcome: a randomized primary care studyPsychiatr Serv200960333734319252046
   PubMed Web of Science ®Google Scholar
• ShikiarRRentzABaroneJDuncansonFKatzEPatient satisfaction with ofloxacin (F) and polymyxin B/neomycin/hydrocortisone (C) in the treatment of otitis externa: results from two randomized clinical trialsJ Manage Care Med2002632427
   Google Scholar
• ShikiarRRentzAMSatisfaction with medication: an overview of conceptual, methodologic, and regulatory issuesValue Health20047220421515164810
   PubMed Web of Science ®Google Scholar
• AllanLHaysHJensenNHRandomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer painBMJ200132272951154115811348910
   PubMed Web of Science ®Google Scholar
• GelhornHLStringerSMBrooksAPreferences for medication attributes among patients with type 2 diabetes mellitus in the UKDiabetes Obes Metab201315980280923464623
   PubMed Web of Science ®Google Scholar
• JohnsonFROzdemirSMansfieldCCrohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacyGastroenterology2007133376977917628557
   PubMed Web of Science ®Google Scholar
• JohnsonFRVan HoutvenGOzdemirSMultiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacyJ Neurol2009256455456219444531
   PubMed Web of Science ®Google Scholar
• BrennanVKDixonSIncorporating process utility into quality adjusted life years: a systematic review of empirical studiesPharmacoeconomics201331867769123771494
   PubMed Web of Science ®Google Scholar
• DonaldsonCShackleyPDoes “process utility” exist? A case study of willingness to pay for laparoscopic cholecystectomySoc Sci Med19974456997079032837
   PubMed Web of Science ®Google Scholar
• SwanJSSainfortFLawrenceWFKuruchitthamVKongnakornTHeiseyDMProcess utility for imaging in cerebrovascular diseaseAcad Radiol200310326627412643553
   PubMed Web of Science ®Google Scholar
• BridgesJFStated preference methods in health care evaluation: an emerging methodological paradigm in health economicsAppl Health Econ Health Policy20032421322415119540
   PubMedGoogle Scholar
• BridgesJFHauberABMarshallDConjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task ForceValue Health201114440341321669364
   PubMed Web of Science ®Google Scholar
• RyanMFarrarSUsing conjoint analysis to elicit preferences for health careBMJ200032072481530153310834905
   PubMed Web of Science ®Google Scholar
• RowenDBrazierJHealth utility measurementGliedSSmithPThe Oxford Handbook of Health EconomicsNew York, NYOxford University Press2011788813
   Google Scholar
• TorranceGWMeasurement of health state utilities for economic appraisalJ Health Econ19865113010311607
   PubMed Web of Science ®Google Scholar
• TorranceGWFurlongWFeenyDHealth utility estimationExpert Rev Pharmacoecon Outcomes Res2002229910819807322
   PubMedGoogle Scholar
• MatzaLSCongZChungKUtilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastasesPatient Prefer Adherence2013785586524039408
   PubMed Web of Science ®Google Scholar
• BogelundMVilsbollTFaberJHenriksenJEGjesingRPLammertMPatient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experimentCurr Med Res Opin201127112175218321981417
   PubMed Web of Science ®Google Scholar
• de Bekker-GrobEWEssink-BotMLMeerdingWJKoesBWSteyerbergEWPreferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experimentPharmacoeconomics200927321121919354341
   PubMed Web of Science ®Google Scholar
• de Bekker-GrobEWEssink-BotMLMeerdingWJPolsHAKoesBWSteyerbergEWPatients’ preferences for osteoporosis drug treatment: a discrete choice experimentOsteoporos Int20081971029103718193329
   PubMed Web of Science ®Google Scholar
• GuimaraesCMarraCAColleyLA valuation of patients’ willingness-to-pay for insulin delivery in diabetesInt J Technol Assess Health Care200925335936619619355
   PubMed Web of Science ®Google Scholar
• JendleJTorffvitORidderstraleMEricssonANilsenBBogelundMWillingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme resultsJ Med Econ201215Suppl 21522853443
   PubMedGoogle Scholar
• JendleJTorffvitORidderstraleMLammertMEricssonABogelundMWillingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetesCurr Med Res Opin201026491792320163195
   PubMed Web of Science ®Google Scholar
• ChancellorJAballeaSLawrenceAPreferences of patients with diabetes mellitus for inhaled versus injectable insulin regimensPharmacoeconomics200826321723418282016
   PubMed Web of Science ®Google Scholar
• SadriHContingent valuation of inhaled insulin: a Canadian perspectiveJ Med Econ2007104475487
   Google Scholar
• SadriHMacKeiganLDLeiterLAEinarsonTRWillingness to pay for inhaled insulin: a contingent valuation approachPharmacoeconomics200523121215122716336016
   PubMed Web of Science ®Google Scholar
• DarbaJRestovicGKaskensLPatient preferences for osteoporosis in Spain: a discrete choice experimentOsteoporos Int20112261947195420838770
   PubMed Web of Science ®Google Scholar
• OssaDFBriggsAMcIntoshECowellWLittlewoodTSculpherMRecombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methodsPharmacoeconomics200725322323717335308
   PubMed Web of Science ®Google Scholar
• CascianoRMalangoneERamachandranAGagliardinoJJA quantitative assessment of patient barriers to insulinInt J Clin Pract201165440841421401829
   PubMed Web of Science ®Google Scholar
• SilvermanSCalderonAKawKPatient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysisOsteoporos Int20132472067207723247328
   PubMed Web of Science ®Google Scholar
• BoyeKSMatzaLSWalterKNVan BruntKPalsgroveACTynanAUtilities and disutilities for attributes of injectable treatments for type 2 diabetesEur J Health Econ201112321923020224930
   PubMed Web of Science ®Google Scholar
• EvansMJensenHHBogelundMGundgaardJChubbBKhuntiKFlexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off surveyJ Med Econ201316111357136524111563
   PubMedGoogle Scholar
• HauberABGonzalezJMSchenkelBLoflandJHMartinSThe value to patients of reducing lesion severity in plaque psoriasisJ Dermatolog Treat201122526627521781015
   PubMed Web of Science ®Google Scholar
• LloydANafeesBBarnettAHWillingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitusClin Ther20113391258126721862132
   PubMed Web of Science ®Google Scholar
• OzdemirSJohnsonFRHauberABHypothetical bias, cheap talk, and stated willingness to pay for health careJ Health Econ200928489490119464743
   PubMed Web of Science ®Google Scholar
• AugustovskiFBeratarrecheaAIrazolaVPatient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experimentValue Health201316238539323538191
   PubMed Web of Science ®Google Scholar
• FraenkelLGulanskiBWittinkDPatient treatment preferences for osteoporosisArthritis Rheum200655572973517013870
   PubMed Web of Science ®Google Scholar
• HodgkinsPSwinburnPSolomonDYenLDewildeSLloydAPatient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experimentPatient201251334422077619
   PubMedGoogle Scholar
• AristidesMWestonARFitzGeraldPLe ReunCManiadakisNPatient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experimentValue Health20047444245415449636
   PubMed Web of Science ®Google Scholar
• MohamedAFZhangJJohnsonFRAvoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferencesDiabetes Metab201339539740323880594
   PubMedGoogle Scholar
• SchmiederASchaarschmidtMLUmarNComorbidities significantly impact patients’ preferences for psoriasis treatmentsJ Am Acad Dermatol201267336337222015150
   PubMed Web of Science ®Google Scholar
• SchaarschmidtMLUmarNSchmiederAPatient preferences for psoriasis treatments: impact of treatment experienceJ Eur Acad Dermatol Venereol201327218719822225546
   PubMed Web of Science ®Google Scholar
• AristidesMChenJSchulzMWilliamsonEClarkeSGrantKConjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancerPharmacoeconomics2002201177578412201796
   PubMed Web of Science ®Google Scholar
• BridgesJFMohamedAFFinnernHWWoehlAHauberABPatients’ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysisLung Cancer201277122423122369719
   PubMed Web of Science ®Google Scholar
• LangerCJFastenauJMForlenzaJBEffectiveness versus convenience: patient preferences for an erythropoietic agent to treat cancer-related anemiaCurr Med Res Opin2007231859217257469
   PubMed Web of Science ®Google Scholar
• PolsterMZanuttoEMcDonaldSConnerCHammerMA comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetesJ Med Econ201013465566121034377
   PubMedGoogle Scholar
• PorzsoltFClouthJDeutschmannMHipplerHJPreferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care valuesHealth Qual Life Outcomes2010812521050469
   PubMed Web of Science ®Google Scholar
• ShafeyMLupichukSMDoTOwenCStewartDAPreferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experimentBone Marrow Transplant201146796296920935681
   PubMed Web of Science ®Google Scholar
• WongMKMohamedAFHauberABPatients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinomaJ Med Econ20121561139114822808923
   PubMedGoogle Scholar
• HauberABHanSYangJCEffect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesPatient Prefer Adherence2013793794924086104
   PubMed Web of Science ®Google Scholar
• SchaarschmidtMLSchmiederAUmarNPatient preferences for psoriasis treatments: process characteristics can outweigh outcome attributesArch Dermatol2011147111285129422106115
   PubMedGoogle Scholar
• LichtensteinGRWatersHCKellyJAssessing drug treatment preferences of patients with Crohn’s disease: a conjoint analysisPatient201032113123
   Google Scholar
• FDA Patient Preference Information – Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling Draft Guidance for Industry, Food and Drug Administration Staff, and Other StakeholdersSilver Spring, MDCenter for Biologics Evaluation and Research (CBER)5201526
   Google Scholar
• GuimaraesCMarraCAColleyLSocioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetesDiabetes Technol Ther200911956757319764835
   PubMed Web of Science ®Google Scholar
• GuimaraesCMarraCAGillSA discrete choice experiment evaluation of patients’ preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes managementPatient Prefer Adherence2010443344021301591
   PubMed Web of Science ®Google Scholar
• PintoSLHoliday-GoodmanMBlackCDLeschDIdentifying factors that affect patients’ willingness to pay for inhaled insulinRes Social Adm Pharm20095325326119733826
   PubMed Web of Science ®Google Scholar
• SungLAlibhaiSMEthierMCDiscrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropeniaJ Clin Epidemiol201265662763422424607
   PubMed Web of Science ®Google Scholar
• TeuffelOChengSEthierMCHealth-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patientsSupport Care Cancer201220112755276422350594
   PubMed Web of Science ®Google Scholar
• ShinglerSLSwinburnPAliSPerardRLloydAJA discrete choice experiment to determine patient preferences for injection devices in multiple sclerosisJ Med Econ20131681036104223730944
   PubMedGoogle Scholar